Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918799 | 0.91 | LMNA (0.48) | LMNAALDH1A1NR1I2CYP1A2HTT | |
| Trifluoroacetic Acid SCHEMBL1122029 | 0.85 | LMNA (0.35) | LMNA | |
| SCHEMBL882914 | 0.85 | LMNA (0.44) | LMNAALDH1A1USP2CYP1A2THRB | |
| SCHEMBL7277164 | 0.85 | LMNA (0.42) | LMNAALDH1A1USP2 | |
| SCHEMBL14478629 | 0.78 | LMNA (0.38) | LMNAALDH1A1USP2CYP1A2THRB | |
| SCHEMBL16134391 | 0.78 | USP2 (0.42) | LMNAALDH1A1USP2CYP1A2THRB | |
| SCHEMBL14481872 | 0.78 | LMNA (0.38) | LMNAALDH1A1USP2CYP1A2THRB | |
| SCHEMBL12386550 | 0.76 | LMNA (0.39) | LMNAALDH1A1TDP1THRB | |
| SCHEMBL3334101 | 0.76 | USP2 (0.45) | LMNAALDH1A1USP2THRB | |
| SCHEMBL13083028 | 0.76 | USP2 (0.41) | LMNAALDH1A1USP2CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0326029-B1 | Antibiotic A 42867 derivative | LEPETIT SPA (IT) | 1994-09-21 | — | — | EP | claimed |
| US-4908351-A | Pseudoaglycon | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-13 | — | — | US | claimed |
| EP-0177882-B1 | ANTIBIOTIC A 40926 COMPLEX AND ITS PURE FACTORS PA, PB, A, B AND BO | GRUPPO LEPETIT S.p.A. (IT) | 1990-01-03 | — | — | EP | claimed |
| EP-0326029-A2 | Antibiotic A 42867 derivative | GRUPPO LEPETIT S.p.A. (IT) | 1989-08-02 | — | — | EP | claimed |
| US-10294262-B2 | 7-deazapurine nucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2019-05-21 | — | — | US | disclosed |
| US-20170240584-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR,V.V.I. (CZ) | 2017-08-24 | — | — | US | disclosed |
| US-9624257-B2 | 7-deazapurine nucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) | 2017-04-18 | — | — | US | disclosed |
| US-20160318970-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) | 2016-11-03 | — | — | US | disclosed |
| EP-2415776-B1 | Beta-L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis B | NOVARTIS AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-9321800-B2 | 7-deazapurine nucleosides for therapeutic uses | GILEAD SCIENCES, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-20150218201-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2015-08-06 | — | — | US | disclosed |
| EP-0463393-A2 | A mutant of bacillus subtiles and a method of producing surfactin with the use of the mutant | ENIRICERCHE S.p.A. (IT) | 1992-01-02 | — | — | EP | disclosed |
| WO-1991002735-A1 | CHEMICAL COMPOUNDS BASED ON A NETROPSIN OR DISTAMYCIN MOLECULE COUPLED WITH AN INTERCALATING AGENT, METHOD FOR PREPARING SAID COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1991-03-07 | — | — | WO | disclosed |
| US-4978757-A | BACTERICIDES, ANTITUMOR AGENTS, UV RAD ABSORBERS | THE UPJOHN COMPANY (US) | 1990-12-18 | — | — | US | disclosed |
| US-4912227-A | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds | THE UPJOHN COMPANY (US) | 1990-03-27 | — | — | US | disclosed |
| US-4908351-A | Pseudoaglycon | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-13 | — | — | US | disclosed |
| EP-0326029-A2 | Antibiotic A 42867 derivative | GRUPPO LEPETIT S.p.A. (IT) | 1989-08-02 | — | — | EP | disclosed |
| EP-0306645-A2 | Teicoplanin-like derivatives | GRUPPO LEPETIT S.P.A. (IT) | 1989-03-15 | — | — | EP | disclosed |
| EP-0246975-A1 | Immuno-suppressive compounds, their preparation by cultivating streptomyces sp. (cbs 162.86) and pharmaceutical compositions containing them | RHONE-POULENC SANTE (FR) | 1987-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218201-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | TPMT, TYMP, ENTPD5 | LMNA 3934/4885ALDH1A1 377/4885USP2 4235/4885 |
| US-10294262-B2 | 7-deazapurine nucleosides for therapeutic uses | TPMT, TYMP, ENTPD5 | LMNA 3601/4885ALDH1A1 368/4885USP2 4529/4885 |
| US-20160318970-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | TPMT, TYMP, ENTPD5 | LMNA 3961/4885ALDH1A1 381/4885USP2 4213/4885 |
| US-20170240584-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | TPMT, TYMP, ENTPD5 | LMNA 3934/4885ALDH1A1 377/4885USP2 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.